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STRESS-FREE CONDIT IONS 
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SUMMARY 
The central nucleus of the amygdala (CeA) is known to be involved in the regulation of autonomic, 
neuroendocrine, and behavioural responses in stress situations. The CeA contains large numbers 
of corticotropin-releasing hormone (CRH)-containing cell bodies and terminals. In the present 
study we examined (by continuous behaviour observations) the effects of a high close of CRH (150 
rig) and two doses of the CRH-receptor antagonist (a-hCRH: 1.0 and 0.1 p,g) after microinfusion 
into the CeA in freely moving male Wistar rats under stress-flee conditions. In comparison with 
control, a-hCRH infusion did not cause any behavioural activation. In contrast CRH-infusion 
revealed a long-lasting increase in grooming and exploration with a concomitant decrease in behav- 
iours specified as resting. These results indicate that the CRH system in the CeA does not seem 
to be activated in stress-free conditions, but its activation is of importance for active behavioural 
responses. 
Keywords--Central nucleus of the amygdala (CeA); Stress-free conditions; Corticotropin-releasing 
hormone (CRH); a-Helical CRH (CRH-receptor antagonist). 
INTRODUCTION 
CORTICOTROPIN-RELEASING HORMONE (CRH), a 41-amino-acid peptide, is considered to 
be a common mediator of stress responses via behavioural, autonomic, and neuroendo- 
crine mechanisms (Cole & Koob, 1991; Davis, 1992; Fisher, 1989). Independent of its 
adrenocorticotropic properties, numerous tudies on the effects of intracerebroventricu- 
lar (ICV) CRH injections reveal overall increases in blood pressure, heart rate (Brown 
& Fisher, 1985; Diamant & De Wied, 1991; Fisher et al., 1983; Korte et al., 1993; 
Kurosawa et al., 1986), plasma catecholamine l vels (Bakke et al., 1990; Brown & Fisher, 
1985; Korte et al., 1993; Kurosawa et al., 1986), glucose levels (Brown, 1986; Brown et 
al., 1982), as well as increases in emotionality, fear, and behavioural activity (Cole & 
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Koob, 1991; Diamant & De Wied, 1991; Dunn & Berridge, 1990; Koob et al., 1992; 
Korte et al., 1993; Morley & Levine, 1982; Thatcher-Britton etal., 1986), and decreases 
in feeding behaviour in different species (Bray, 1992; Dunn & Berridge, 1990; Glowa & 
Gold, 1991; Gosnell et al., 1983; Morley & Levine, 1982, 1990; Morley et al., 1985). 
Despite these numerous tudies, the exact anatomical sites responsible for the CRH 
(ICV)-induced actions are less understood. 
CRH cell bodies and fibers are located heterogeneously throughout the central nervous 
system. One of the areas in which a high density of CRH neurons is found, is the 
central nucleus of the amygdala (CeA), which innervates the periaquaductal gray and 
the brainstem autonomic nuclei (Danielsen et al., 1989~ Gray, 1990a, 1990b; Gray & 
Magnuson, 1987; Sakanaka et al., 1986). 
In a previous study, we have found that local application of a low dose of CRH (30 
ng) in the central nucleus of the amygdala (CeA) led to an increase in cardiac response, 
while this was blocked by the CRH-receptor antagonist, c~-hCRH (Wiersma et al., 1993). 
However, infusion of two doses, 0. l and 1.0 ~g, of ~-hCRH + CRH (30 ng), resulted 
in an elevation in plasma corticosterone, an effect which was not observed in CRH 
treated animals alone. Besides, the CRH-induced behavioural activation was not com- 
pletely blocked by pretreatment of 0.1 and 1.0 ~g ~-hCRH. It was suggested that the 
CRH-antagonist may have possible agonistic properties. Indeed some agonistic properties 
of ~-hCRH after ICV administration were already described (Baldwin et al., 1991; Ber- 
ridge & Dunn, 1987; Winslow et al., 1991). 
The present study was designed to substantiate he suggestion that the CRH-antagonist 
may have possible agonistic properties under stress-free conditions. The aim of this study 
was to compare the behavioural effects of a high dose of CRH (150 ng) after local infusion 
into the CeA, to the behavioural responses of the CRH-receptor antagonist after intra- 
CeA microinfusions. 
As some studies indicate that the effects of CRH or its receptor antagonist may depend 
on the activational state of the CRH system, the experiments were carried out under 
stress-free resting conditions (Diamant, 1991; Diamant & De Wied, 1991; Krahn et al., 
1986). Moreover, several studies suggest hat the CRH system is somehow involved in 
food intake as well (Cole & Koob, 1991; Gosnell et al., 1983; Morley & Levine, 1990). 
For that reason, the experiments were performed in the presence of fresh food pellets. 
MATERIALS AND METHODS 
Experimental Animals 
Fifteen male Wistar rats, weighing 290-318 g at the beginning of the experiment, were 
used. The animals were housed individually in Perspex cages (25 × 25 × 30 cm) and 
kept in a temperature controlled room (20 _+ 2°C) with a 12-h light-dark cycle (lights on 
from 0830 to 2030h). The experiment was performed uring the light period of the cycle 
(between 0930 and 1430h). Food and water were available ad lib. 
Surgery 
Each experimental nimal was first provided with bilateral permanent stainless-steel 
brain cannulas (outer diameter 0.3 mm, inner diameter 0.15 mm) for drug infusion, aimed 
just above the central amygdala (coordinates: 6.7 mm rostral to interaural, lateral 4.0 
mm to the midline and ventral 6.2 mm below the dura) according to Paxinos and Watson 
(1982). The cannulas were implanted stereotaxically and fixed onto the skull by means 
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of stainless-steel screws and dental cement. The animals were kept under ether anesthesia 
during the entire surgical procedure. 
Drug Treatment 
Synthetic rat/human CRH (CRF; Sigma Chemical Co., St. Louis, MO) and the CRH 
receptor antagonist, c~-helical CRH9-41 (~-hCRF; Sigma Chemical Co., St. Louis, MO) 
were dissolved in artificial cerebrospinal fluid (aCSF) with ascorbic acid (100 ~g/ml 
aCSF). CRH was administered in a dose of 150 ng/rat per cannula, c~-hCRH at low dose 
of 0.1/~g (c~-hCRH 0. I/~g) and high dose of 1/~g/rat (~-hCRH 1.0/.Lg) per cannula, q'he 
dosages of c~-hCRH used are known to antagonise dose-dependently theCRH-induced 
responses after local application i to the CeA in stress-free and stress ituations (Wiersma 
et al., 1993; Wiersma et al., in preparation). The vehicle was sterile artificial cerebrospinal 
fluid (aCSF) containing 127.64 mM NaCl, 2.55 mM KCI, 1.26 mM CaCI:, and 0.93 mM 
MgCI2'6H20. All compounds were infused in a total volume of I gl in each cannula 
during a 7-rain period. 
Behavioural Measurements 
Behaviour was recorded on the basis of the following criteria: 
• Resting/sleeping: inactive with eyes open or closed. 
• Immobility: completely motionless, absence of skeletal and vibrissae movements ex- 
cept those associated with respiration. 
• Exploring: investigation of any part of the home cage. 
• Grooming: wiping the fur with forepaws and tongue (washing). 
• Burying: pushing the bedding material with rapid movements ofthe snout or forepaws. 
• Rearing: sniffing in the air with both forepaws from the floor. 
• Eating: chewing food. 
• Sniffing: sniffing in the air with paws on the floor. 
The various behavioural elements were recorded continuously by means of a keyboard 
operated microprocessor (EDB, Haren, The Netherlands). The duration and the fre- 
quency of these elements were recorded and expressed as the percentage of the total 
observation period. 
Experimental Procedures 
The experiments were performed in the animals' home cages under stress-free condi- 
tions. The rats were trained to habituate to the infusion procedure for at least a few 
hours during 2 days before the start of the experiments. After at least l0 days recovery 
from surgery, the rats were tested for the first time. A random treatment design was 
used in which each rat served as its own control, and received each treatment. Each 
treatment was separated by a wash-out period of at least 1 week. At t = -40 rain, the 
rats were weighed. Subsequently after emoval of the cap and obturator, the polyethylene 
tubing was connected to each cannula. The tubing was filled with the drug infusion 
solution. The animal was returned to his homecage and the tubing was counterbalanced. 
At the same time all the food in the cage was removed. At t = 0 min, a dish with fresh 
food pellets was placed in the cage. The microinfusion started then immediately. After 
termination ofthe infusion the behavioural observations started. Continuous observations 
over 63 rain were made, subdivided into periods of 7-min each. 
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FIG. l: Duration of exploration (--SEM), during and after microinfusion i to the CeA of artificial 
CSF, 150 ng CRH, or the CRH-receptor antagonist (~-hCRH) in two doses (1.0 and 0.1 txg). At 
t = 0 rain, a plate with fresh food pellets was placed in the cage. The infusion period is indicated 
by the black horizontal bar. 
Histology 
At the end of the experiments, the rats were deeply anesthetized with sodium pentobar- 
bital (90 mg/kg IP) and perfused intracardially with saline followed by a 4% formaldehyde 
solution. The brains were postfixed in the same fixative for at least 1 week. Frozen 
sections of 40/zm were cut and the location of the tip of the cannula was determined 
on unstained sections. 
Statistical Analysis 
The behavioural data were evaluated using an analysis of variance with repeated 
measures (ANOVA), followed by the correlated Student's t- test. A probability level of 
p < .05 was taken as criterion for significance. 
RESULTS 
Histological examination revealed that three of the animals had to be excluded from 
further analysis because of improper bilateral cannula placement. The cannulae tips had 
to be localized just above or entering the dorsal edge of the CeA. 
The CRH treatment showed pronounced effects on locomotion activity (Fig. 1). The 
CRH treated animals showed significant more exploring activities compared to the CRH 
antagonist treated animals and the vehicle group in both the repeated measures ANOVA 
[ANOVA treatment: CRH-aCSF, F(1, 22) = 16.12 p < .001; CRH-ahCRH 0.1/zg, F(1, 
22) = 14.06p < .005; CRH-o~hCRH 1.0/zg, F(1, 22) = 15.83 p < .001] and the Student's 
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FIo. 2: Duration of grooming (-+SEM), during and after microinfusion i to the CeA of artificial 
CSF, 150 ng CRH, or the CRH-receptor antagonist (a-hCRH) in two doses (1.0 and 0.1 /zg). At 
t = 0 min, a plate with fresh food pellets was placed in the cage. The infusion period is indicated 
by the black horizontal bar. 
t-test (significance between the groups started at the fourth time interval and lasted till 
the last measurement). 
Also, the immobility response was slightly increased in the CRH-treated animals, but 
this result was not as clear as the results of exploring and resting responses [treatment: 
CRH-aCSF, F(I,  22) = 5.31 p < .05; CRH-ahCRH 0.1 p.g, F(1, 22) = 0.056 p = .80; 
CRH-ahCRH 1.0/xg, F(1, 22) = 8.30 p < .01]. 
The CRH treatment also caused a significant increase in grooming (Fig. 2) compared 
to the three other groups during the whole 63-min observation period [ANOVA treatment: 
CRH-aCSF, F(I ,  22) = 8.20p < .01; CRH-ahCRH 0.1 /zg, F(I,  22) = 15.09 p < .01)5; 
CRH-ahCRH 1.0 ~g, F(1, 22) = 13.629 p < .005]. 
The infusion ofaCSF, and both concentrations of the CRH-receptor antagonist resulted 
in a steady increase in resting behaviour to 90% of the total time observed at the end 
of the observation period (Fig. 3). However, the CRH infusion caused only a small 
increase in resting behaviour, which resulted in a maximum of 40% of the total time 
spent resting at the last time interval (Fig. 1). Comparing the CRH with all the other 
treatments analysis of variance showed highly significant treatment effects [CRH-aCSF, 
F(1, 22) = 15.68 p < .001; CRH-c~hCRH 0.1/zg, F(I,  22) = 14.44p < .005; CRH-ahCRH 
1.0 /zg, F(1, 22) = 24.18 p < .0005]. Also significant differences between time and 
group x time interactions were found. The Student's t-test revealed that the significant 
decreases in the CRH compared with both of the CRH-receptor antagonist treatments 
started at the third observation time interval, whereas the significant differences between 
the vehicle and the CRH treatment started at the second time interval and lasted until 
the end of the total observation period. 
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FIG. 3: Duration of resting (-+SEM), during and after microinfusion i to the CeA of artificial CSF, 
150 ng CRH, or the CRH-receptor antagonist (c~-hCRH) in two doses (1.0 and 0.1 ~g). At t = 0 
min, a plate with fresh food pellets was placed in the cage. The infusion period is indicated by 
the black horizontal bar. 
No differences were found between the three treatment groups and the vehicle group 
in the other observed behaviours. 
DISCUSSION 
The main findings of the present experiment were that local application of a high dose 
of CRH into the CeA resulted in a long-lasting increase in exploration and grooming 
behaviour, with a concomitant decrease intime spent resting during the entire observation 
period. Administration ofthe CRH-receptor antagonist in two concentrations i  the CeA 
did not cause discernible ffects on behaviour in rats under stress-free conditions. 
The increase in behavioural ctivity, especially locomotor and grooming activities, as 
a result of the CRH infusion in the CeA in the rats' home cage, is consistent with 
observations that CRH administered both ICV (Diamant & De Wied, 1991; Eaves et al., 
1985; Sutton et al., 1982) and locally into the CeA produces behavioural ctivation in 
the rat (Lee & Sung, 1989; Lee & Tsai, 1989; Wiersma et al., 1993). However, CRH 
infusion in the CeA, in a dose five times lower as the dose used in the present study, 
did not result in an excessive grooming response (Wiersma et al., 1993). This suggest 
that CRH administration at high doses in the CeA induces a nonspecific behavioural 
response. This assumption is in accordance with the results of ICV CRH applications 
(Britton et al., 1982; Diamant & De Wied, 1991; Morley & Levine, 1982; Sherman & 
Kalin, 1988; Spruijt et al., 1992). It was suggested that the threshold for CRH to induce 
grooming may depend on the testing conditions (Diamant & De Wied, 1991; Dunn & 
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Berridge, 1990). At low doses, CRH was found sufficient o induce grooming when rats 
were treated in a shock chamber, whereas higher doses were necessary to produce a 
similar effect when rats were tested in an open field or the home cage (Diamant & De 
Wied, 1991 ; Morley & Levine, 1982; Thatcher-Britton etal., 1986; Veldhuis & De Wied, 
1984). Excessive grooming may represent a displacement activity during an increased 
arousal state and it probably serves as restoration of the homeostatic status of the rat 
(Cohen & Price, 1979; Jolles et al., 1979; Sherman & Kalin, 1988; Spruijt et al., 1992). 
The finding that a-hCRH in the CeA fails to affect behavioural ctivation in the stress- 
free condition supports the results of different reports injecting CRH and the antagonist 
in the ventricles (ICV), suggesting that while the CRH-antagonist blocked CRH-induced 
and stress-induced effects (Baldwin et al., 1991; Berridge & Dunn, 1987; Cole et al., 
1992; Heinrichs et al., 1992; Tazi et al., 1987), the CRH antagonist had no agonistic 
effect of its own (Cole & Koob, 1991; Heinrichs et al., 1992; Krahn et al., 1986; 
Thatcher-Britton et al., 1986). For example, Krahn and colleagues (1986) found that 
after ICV a-hCRH administration, the CRH antagonist did not change food intake in 
fasted but otherwise unstressed rats. However, this finding stands in contrast o the 
increase in feeding with ICV administration ofa-hCRH seen after CRH treatment (Krahn 
et al., 1986). They suggest hat the direction of feeding effects of a-hCRH is dependent 
on the state of the CRH system in the subject ested. Furthermore, in a recent study, 
intra-amygdaloid administration of the CRH-antagonist dose-dependently reversed the 
effect of exposure to an aggressive resident, without altering the behaviour of unstressed 
rats (Heinrichs et al., 1992). The results of the present and previous studies (Wiersma 
et al., 1993), infusing the CRH-receptor antagonist into the CeA under stress-free and 
CRH-activated conditions, are in agreement with the results of Krahn and collegues 
(1986) after ICV and Heinrichs and co-workers (1992) after intra-amygdaloid a ministra- 
tion. This suggests that the CeA may be the possible anatomical localization which can 
be responsible for some of the ICV CRH-induced and ICV a-hCRH-induced behavioural 
responses. 
In the present study no effects of either a-hCRH or CRH treatment on feeding behav- 
iour was observed. CRH given ICV is known to influence metabolism by eliciting an 
increase in plasma concentration of glucagon and glucose and a decrease in plasma 
insulin levels (Brown, 1986; Brown et al., 1982), which in turn results in a decrease in 
feeding behaviour (Bray, 1992; Dunn & Berridge, 1990; Glowa & Gold, 1991; Gosnell 
et al., 1983; Levine et al., 1983; Morley & Levine, 1982, 1990; Morley et al., 1985). On 
the other hand, ICV injection of the CRH receptor antagonist partially reversed the 
CRH- or stress-induced anorexic effects. It seems that the paraventricular nucleus of 
the hypothalamus (PVN) is the site within the central nervous system at which CRH 
produces its inhibitory effect on feeding, as studies with intrahypothalamic infusions 
revealed that only CRH in the PVN dose-dependently increased serum glucose levels 
(Cole & Koob, 1991; Gunion et al., 1988; Morley & Levine, 1990). As no direct CRH 
projections from the CeA to the PVN are known (Gray, 1990b) and no effect on feeding 
behaviour after either CRH or CRH-antagonist infusion in the CeA occurred (Wiersma 
et al., 1993), it appears that the CeA is probably not involved in the ICV CRH-induced 
decrease in feeding response. 
In conclusion, our results and earlier work done in this laboratory reveal that the CeA 
may be responsible for some of the ICV CRH-induced behavioural activation, such as 
the dose-dependent increase in grooming, and the activation in exploring responses. 
Further, the present study shows that the c~-hCRH infusion in the CeA under stress- 
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free conditions does not have any behavioural effects. Probably, the possible agonistic 
properties of a -hCRH depends on the activational state of the total CRH system in the 
CNS. In the present experiment we assumed that the CRH system was not activated as 
a result of the stress-free conditions. It is known that the CRH system in the CNS will 
react differently to the same stimuli if the CRH system is activated, in stress situations, 
or not, in stress-free situations. The present results are in accordance with the idea that 
the CRH system in the CeA is not activated in stress-free conditions. 
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